Premium
Cost‐effectiveness of bevacizumab‐based therapy versus cisplatin plus pemetrexed for the first‐line treatment of advanced non‐squamous NSCLC in Korea and Taiwan
Author(s) -
AHN MyungJu,
TSAI ChunMing,
HSIA TeChun,
WRIGHT Elaine,
CHANG John WenCheng,
KIM Heung Tae,
KIM JooHang,
KANG Jin Hyoung,
KIM SangWe,
BAE EunJin,
KANG Mijeong,
LISTER Johanna,
WALZER Stefan
Publication year - 2011
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/j.1743-7563.2011.01399.x
Subject(s) - pemetrexed , medicine , oncology , bevacizumab , gemcitabine , incremental cost effectiveness ratio , cost effectiveness , life expectancy , cost effectiveness analysis , cisplatin , lung cancer , economic evaluation , cancer , chemotherapy , environmental health , population , risk analysis (engineering) , pathology
Aims: The aim of this analysis is to investigate the mean incremental costs and life expectancy associated with two first‐line treatments for advanced non‐squamous non‐small cell lung cancer (NSCLC) in Korea and Taiwan; bevacizumab plus cisplatin and gemcitabine (BevCG) and cisplatin plus pemetrexed (CP). Methods: A health economic (area under curve) model with three health states was developed to assess health outcomes (life‐years gained [LYG]), direct costs, and incremental cost‐effectiveness ratio (ICER). Progression‐free survival (PFS) and overall survival (OS) were derived from randomized clinical trials and used in an indirect comparison in order to estimate their cost effectiveness. A life‐time horizon was used. Costs and outcomes were discounted yearly by 5% in Korea and by 3% in Taiwan. Results: The incremental LYG for the BevCG patients compared with patients treated with CP were 1.10 (13.2 months) in Korea and 1.19 (14.3 months) in Taiwan. The incremental costs were 37 439 968 ($33 322) in Korea and NT$1 910 615 ($64 541) in Taiwan. The incremental cost‐effectiveness ratio was 34 064 835 ($30 318) in Korea and NT$1 607 960 ($54 317) in Taiwan. The inputs tested in one‐way sensitivity analyses had very little impact on the overall cost effectiveness. Conclusion: This analysis shows that BevCG is more costly but is also associated with additional life‐years in Korea and Taiwan. The ICER per LYG suggests that BevCG is a cost‐effective therapy when compared to CP for patients with advanced NSCLC in Korea and Taiwan.